University of Leuven Selects GenoLogics Solution for Lab and Data Management
News Nov 16, 2006
GenoLogics Life Sciences Software Inc. (GenoLogics), has announced the ProMeta Interfaculty Centre for Proteomics and Metabolomics at Belgium’s University of Leuven has selected GenoLogics’ Proteus™ as the lab and scientific data management solution for its proteomics and metabolomics research.
The ProMeta Centre specializes in providing mass spectrometry and chromatography-based technology services (such as MALDI-TOF/TOF-MS, 2D LC-MS, and FT-MS), complemented by its capability of handling gel-based proteomics samples, to proteomics and metabolomics researchers.
GenoLogics’ Proteus™ solution will provide benefits to ProMeta including increased automation of instruments and data integration with downstream search engine processes such as Sequest and Mascot, resulting in more efficient provision of services to ProMeta’s academic and industry clients.
ProMeta expects to realize a decrease in turnaround time, thus increasing profitability by implementing Proteus at the centre.
Professor Etienne Waelkens, leader of the ProMeta initiative, appreciated GenoLogics’ commitment to the rapidly evolving fields of proteomics and metabolomics. Professor Waelkens stated,
“GenoLogics’ knowledge of our industry, and their flexibility and independence from instrument vendors, which lets us choose the best equipment and instruments, influenced our decision to choose Proteus.”
Professor Waelkens added, “When we were considering solution providers, GenoLogics was set apart by their commitment to partnership and collaboration. We are pleased that GenoLogics will be partnering with us to evaluate the commercial merits of using Proteus in ancillary applications such as MALDI imaging, which is currently being explored by our researchers.”
GenoLogics is committed to developing a long-term partnership with ProMeta and supporting its mandate of being a centre of excellence for mass spectrometry.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.